T1	Premise 1563 1715	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).
T2	Premise 1105 1227	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).
T3	Premise 1725 1821	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.
T4	Premise 1822 1878	Although toxicity was higher in patients receiving FLOT,
T5	Premise 1879 1967	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.
T6	Claim 1974 2101	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.
R1	Partial-Attack Arg1:T5 Arg2:T4	
R2	Attack Arg1:T4 Arg2:T6	
R3	Support Arg1:T3 Arg2:T6	
R4	Support Arg1:T1 Arg2:T6	
R5	Support Arg1:T2 Arg2:T6	
